Filing Details

Accession Number:
0001209191-18-028866
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-05-09 16:24:15
Reporting Period:
2018-05-07
Accepted Time:
2018-05-09 16:24:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
820081 Cambrex Corp CBM Pharmaceutical Preparations (2834) 222476135
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1227835 Gregory Sargen One Meadowlands Plaza
East Rutherford NJ 07073
Evp, Corporate Development No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-05-07 30,000 $0.00 50,000 No 4 A Direct
Common Stock Disposition 2018-05-07 23,002 $49.46 26,998 No 4 S Direct
Common Stock Acquisiton 2018-05-08 7,500 $16.91 34,498 No 4 A Direct
Common Stock Acquisiton 2018-05-08 7,500 $17.81 41,998 No 4 A Direct
Common Stock Acquisiton 2018-05-08 15,000 $41.36 56,998 No 4 A Direct
Common Stock Acquisiton 2018-05-08 7,500 $40.65 64,498 No 4 A Direct
Common Stock Disposition 2018-05-08 10,565 $49.05 53,933 No 4 S Direct
Common Stock Disposition 2018-05-08 33,933 $49.63 20,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 A Direct
No 4 A Direct
No 4 A Direct
No 4 A Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2018-05-08 7,500 $0.00 7,500 $16.91
Common Stock Stock Option (right to buy) Acquisiton 2018-05-08 7,500 $0.00 7,500 $17.81
Common Stock Stock Option (right to buy) Acquisiton 2018-05-08 15,000 $0.00 15,000 $41.36
Common Stock Stock Option (right to buy) Acquisiton 2018-05-08 7,500 $0.00 7,500 $40.65
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2020-10-28 No 4 M Direct
7,500 2021-10-22 No 4 M Direct
15,000 2022-10-21 No 4 M Direct
22,500 2023-10-26 No 4 M Direct
Footnotes
  1. Pursuant to settlement of a performance share award.
  2. Broker-assisted sale of which 14,805 shares were to cover the payment of withholding tax liability from the settlement of a performance share award.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.20 to $49.875 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.50 to $49.45 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 4 to this Form 4.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.50 to $49.85 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 5 to this Form 4.
  6. The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 28, 2014, which was the first anniversary of the date on which the option was granted.
  7. The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 22, 2015, which was the first anniversary of the date on which the option was granted.
  8. The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 22, 2016, which was the first anniversary of the date on which the option was granted.
  9. The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 26, 2017, which was the first anniversary of the date on which the option was granted.